Trial intelligence / Profile preview

Asciminib versus investigator-selected TKI in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

MOH_2021-12-26_010464Phase 3Active, not recruiting

Sponsor

Novartis

Start

Nov 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1